Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS ...

The US Food and Drug Administration has accepted Sobi’s supplemental biologics licence application for Gamifant (emapalumab-Izsg) for haemophagocytic lymphohistiocytosis (HLH)/macrophage ...

The EMBRACE Phase 2a study will adopt a precision immunotherapy approach for the treatment of sepsis driven by the IDS ...

Switzerland’s Novimmune has filed its rare disease drug emapalumab in Europe, days after it sealed a deal selling rights to Sweden’s Sobi. The biotech, based in Geneva and Basel, has filed for ...

Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS ...

Swedish Orphan Biovitrum AB (Sobi), a specialised international biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License ...

Sobi announces a new research collaboration on the development of Gamifant in sepsis, which is to be presented at the ISICEM congress: Stockholm Thursday, March 20, 2025, 12:00 Hr ...

IDS is a new endotype representing approximately 20 percent of sepsis patients and is characterised by detection of IFNγ (above lower limit of detection) and elevated levels of the chemokine CXCL9.

IDS is a new endotype representing approximately 20 percent of sepsis patients and is characterised by detection of IFNγ (above lower limit of detection) and elevated levels of the chemokine CXCL9.